Criteria for the clinical use of immunogloulin

Criteria for the clinical use of immunogloulin

The Criteria for Immunoglobulin Use in Australia (the Criteria) is changing to Version 3. These changes will apply in BloodSTAR from 22 October 2018.

The criteria is changing:

  • To align with new evidence
  • To ensure those whose health is most likely to be improved with Ig therapy can get it
  • To manage the growth in demand for this precious, human-derived product.

Some current authorisations will move to the new Criteria automatically, while others may require prescribers to provide more information at the next patient review.

For more information please visit the National Blood Authority website.